Altering the course of cancer — permanently

We are delivering transformative therapies by harnessing the potential of covalent medicines and chemical proteomics coupled with deep human translational insights.

Pioneering the next-generation of therapies by widening the landscape of druggable targets to create durable treatments for cancer patients

We are integrating comprehensive chemical proteomics, innovative covalent-based molecular technologies, and translational insights from patients to create unique strategies to target high-value, hard to drug cancer-promoting proteins and to overcome resistance to existing treatments.

Chemical Proteomics, Covalent Technology, TranslationalInsights

Our team unites world-class academic founders, seasoned investors, and a proven leadership group with a distinguished track record of building successful biotech companies and delivering impactful cancer therapies to patients.

Our investors provide strategic guidance, deep industry insight, and strong networks to support the growth, scale and success of Monimoi